Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. 

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Feature | Treatment Planning | By Melinda Taschetta-Millane
Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

Time March 05, 2021
arrow
CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.
Feature | Radiation Dose Management | By Dave Fornell
Medical Imaging Radiation Exposure in U.S. Dropped Over Past Decade

More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that was ...

Time March 04, 2021
arrow
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer
News | PET-CT
Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which ...

Time February 23, 2021
arrow
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.
News | Molecular Imaging
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

February 22, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2 ...

Time February 22, 2021
arrow
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti
News | PET Imaging
Imaging Identifies Breast Cancer Patients Unlikely to Benefit from Hormone Therapy

February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry ...

Time February 03, 2021
arrow
NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

Time January 29, 2021
arrow
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
News | PET Imaging
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time January 18, 2021
arrow
Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep
News | PET Imaging
Imaging the Twilight Zone

December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal ...

Time December 30, 2020
arrow
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.
News | Nuclear Imaging
New Diagnostic Isotope to Enhance Targeted Alpha Therapy for Cancer

December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a ...

Time December 22, 2020
arrow
SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)
News | Nuclear Imaging
SHINE Medical Breaks Ground for 54,000-Square-Foot Headquarters and Therapeutics Production Facility

December 18, 2020 — SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000 ...

Time December 18, 2020
arrow
Researchers at the Beckman Institute for Advanced Science and Technology developed a subspace mass spectrometry imaging approach that accelerates the speed of data acquisition -- without sacrificing the quality -- by designing a model-based reconstruction strategy.
News | SPECT Imaging
Computational Method Provides Faster High-resolution Mass Spectrometry Imaging

December 15, 2020 — A new computational mass spectrometry imaging method enables researchers to achieve high mass ...

Time December 15, 2020
arrow
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.
News | PET Imaging
PET Imaging Tracer Effective for Diagnosing and Managing Rare CNS B-cell Lymphoma

December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for ...

Time December 14, 2020
arrow
News | Nuclear Imaging
The Journal of Nuclear Medicine Celebrates 60 Years of Research

December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of ...

Time December 14, 2020
arrow
Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma
News | PET-MRI
PET/MRI, CT Metrics Assess Pathologic Response of Pancreas Cancer to Neoadjuvant Therapy

December 10, 2020 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR) ...

Time December 10, 2020
arrow
Videos | PET-CT
VIDEO: Example of PET-CT Artificial Intelligence Driven Image Reconstruction

This is an example of Canon's Advanced intelligent Clear-IQ Engine (AiCE) AI-driven image reconstruction software that ...

Time December 04, 2020
arrow
Approval provides access to the first and only 64-slice volumetric CT digital SPECT/CT in the market, technology for routine total body 3D imaging in nuclear medicine departments
News | SPECT-CT
Spectrum Dynamics Receives Approval from Health Canada for VERITON-CT64 Digital SPECT/CT

December 4, 2020 — Spectrum Dynamics Medical, Inc., has received Canadian Medical Device License from Health Canada for ...

Time December 04, 2020
arrow
 Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
News | PET Imaging
Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent in Collaboration with Nucleis Radiopharmaceuticals

November 25, 2020 — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their ...

Time November 25, 2020
arrow
ASG well positioned for growth as healthcare marketplace continues to evolve 
News | Radiology Imaging
Alpha Source Group Names New CEO, Expands Customized Service Solutions to Focus on OEM Partnerships

November 24, 2020 — Alpha Source Group (ASG), a comprehensive next-generation services partner, has named Allan Klotsche ...

Time November 24, 2020
arrow
Spectrum Dynamics Medical, a leading innovator in diagnostic imaging solutions, announces that its VERITON-CT digital SPECT/CT with personalized scans has received a pediatric program contract from Vizient, Inc., a member-driven healthcare performance improvement company in the U.S.
News | SPECT-CT
Spectrum Dynamics Named Vizient Pediatric Provider for VERITON-CT Digital SPECT/CT

November 20, 2020 — Spectrum Dynamics Medical, a leading innovator in diagnostic imaging solutions, announces that its ...

Time November 20, 2020
arrow
 MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) program.
News | Prostate Cancer
MIM Software Inc. Announces Collaboration with Peter MacCallum Cancer Centre to Improve Patient Management

November 19, 2020 — MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in ...

Time November 19, 2020
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now